Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin
2020; Lippincott Williams & Wilkins; Volume: 142; Issue: 3 Linguagem: Inglês
10.1161/circulationaha.120.048238
ISSN1524-4539
AutoresLee S. Nguyen, Charles Dolladille, Milou-Daniel Drici, Charlotte Fenioux, Joachim Alexandre, Jean-Paul Mira, Javid J. Moslehi, Dan M. Roden, Christian Funck‐Brentano, Joe-Élie Salem,
Tópico(s)Antibiotics Pharmacokinetics and Efficacy
ResumoHomeCirculationVol. 142, No. 3Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessLetterPDF/EPUBCardiovascular Toxicities Associated With Hydroxychloroquine and AzithromycinAn Analysis of the World Health Organization Pharmacovigilance Database Lee S. Nguyen, MD, Charles Dolladille, MD, Milou-Daniel Drici, MD, PhD, Charlotte Fenioux, MD, Joachim Alexandre, MD, PhD, Jean-Paul Mira, MD, PhD, Javid J. Moslehi, MD, Dan M. Roden, MD, Christian Funck-Brentano, MD, PhD and Joe-Elie Salem, MD, PhD Lee S. NguyenLee S. Nguyen Sorbonne Université, Institut national de la santé et de la recherche médicale (INSERM), Assistance Publique - Hopitaux de Paris, Clinical Investigation Center, Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France (L.S.N., C.F., C.F.-B., J.-E.S.). Centre Medico-Chirurgical Ambroise Paré, Research & Innovation, Neuilly-sur-Seine, France (L.S.N.). Search for more papers by this author , Charles DolladilleCharles Dolladille Pharmacoepidemiology Unit, Department of Pharmacology, Centre Hospitalo-Universitaire de Caen, Equipe d’accueil EA4650, Signalisation, Electrophysiologie et Imagerie des Lésions d’Ischémie-Reperfusion Myocardique, Normandie University, Caen, France (C.D., J.A.). Search for more papers by this author , Milou-Daniel DriciMilou-Daniel Drici Department of Pharmacology and Toxicology, PharmacoVigilance Center, University of Nice Côte d’Azur Medical Center, Hôpital de Cimiez, France (M.-D.D.). Search for more papers by this author , Charlotte FeniouxCharlotte Fenioux Sorbonne Université, Institut national de la santé et de la recherche médicale (INSERM), Assistance Publique - Hopitaux de Paris, Clinical Investigation Center, Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France (L.S.N., C.F., C.F.-B., J.-E.S.). Search for more papers by this author , Joachim AlexandreJoachim Alexandre Pharmacoepidemiology Unit, Department of Pharmacology, Centre Hospitalo-Universitaire de Caen, Equipe d’accueil EA4650, Signalisation, Electrophysiologie et Imagerie des Lésions d’Ischémie-Reperfusion Myocardique, Normandie University, Caen, France (C.D., J.A.). Search for more papers by this author , Jean-Paul MiraJean-Paul Mira Groupe Hospitalier Paris Centre-Université de Paris, Cochin University Hospital, Medical Intensive Care Unit, France (J.-P.M.). Search for more papers by this author , Javid J. MoslehiJavid J. Moslehi Vanderbilt University Medical Center, Departments of Medicine and Pharmacology (J.J.M., D.M.R., J.-E.S.), Nashville, TN. Search for more papers by this author , Dan M. RodenDan M. Roden Vanderbilt University Medical Center, Departments of Medicine and Pharmacology (J.J.M., D.M.R., J.-E.S.), Nashville, TN. Department of Biomedical Informatics (D.M.R.), Nashville, TN. Search for more papers by this author , Christian Funck-BrentanoChristian Funck-Brentano Sorbonne Université, Institut national de la santé et de la recherche médicale (INSERM), Assistance Publique - Hopitaux de Paris, Clinical Investigation Center, Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France (L.S.N., C.F., C.F.-B., J.-E.S.). Search for more papers by this author and Joe-Elie SalemJoe-Elie Salem Joe-Elie Salem, MD, PhD, Department of Pharmacology, Sorbonne Université, INSERM CIC-1901, AP-HP, Clinical Investigation Center, Pitié-Salpêtrière Hospital, Paris, France, 83 Bld de l’hôpital, 75651 Paris Cedex 13. Email E-mail Address: [email protected] https://orcid.org/0000-0002-0331-3307 Sorbonne Université, Institut national de la santé et de la recherche médicale (INSERM), Assistance Publique - Hopitaux de Paris, Clinical Investigation Center, Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France (L.S.N., C.F., C.F.-B., J.-E.S.). Vanderbilt University Medical Center, Departments of Medicine and Pharmacology (J.J.M., D.M.R., J.-E.S.), Nashville, TN. Search for more papers by this author Originally published22 May 2020https://doi.org/10.1161/CIRCULATIONAHA.120.048238Circulation. 2020;142:303–305Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: May 22, 2020: Ahead of Print Although hydroxychloroquine and azithromycin, alone or in combination, have been proposed for treatment of patients with coronavirus disease 2019 (COVID-19),1 their potential cardiovascular toxicities had limited consideration in this new clinical environment. We aimed to determine whether these drugs were associated with an increased reporting of cardiovascular (CV) adverse drug reactions (ADR) in a real-world population, before start of prescription for COVID-19 in Europe and America.In this observational, retrospective study, we used VigiBase,2,3 the World Health Organization pharmacovigilance database encompassing more than 21 million reports from more than 130 countries, to compare CV-ADR reporting in patients who received hydroxychloroquine, azithromycin, or their combination with CV-ADRs reported with all other drugs in the full database (clinicaltrials.gov identifier NCT04314817). Association between hydroxychloroquine, azithromycin, and their combination with CV-ADR was assessed using reporting odds ratio (ROR) and information component (IC), an indicator value for disproportionate Bayesian reporting that compares observed and expected values to find associations between drugs and ADR.2 The lower end of the IC’s 95% credibility interval is IC025. It is considered significant when above 0.2 Reporting odds ratios were computed to compare ADR frequencies between different exposures, using χ2 tests.3 These methods are similar to those used to study CV-ADR related to anticancer and hormonal drugs.2,3 For each report, age, sex, time to onset (TTO), fatalities, concurrent ADRs, and medications (drugs associated with a known or possible risk of QT prolongation as reported at crediblemeds.org)4 were collected. TTO were compared using nonparametric tests. The French National Commission for Data Protection and Liberties and institutional review board approved the use of confidential electronically processed patient data. All CV-ADRs were included, classified by group queries,2 according to the Medical Dictionary for Regulatory Activities, between November 14, 1967, and March 1, 2020.We extracted 76 822 ADR cases associated with hydroxychloroquine alone, 89 692 with azithromycin alone, and 607 with the combination of both drugs. The cases were retrieved from 21 275 867 total ADR reports in VigiBase. Hydroxychloroquine was a suspected (versus concomitantly used) drug in 21 808/76 822 (28.4%) cases and azithromycin in 54 533/89 692 (60.8%) cases.There was significant greater reporting of prolonged-QT (LQT) and/or ventricular tachycardia including Torsades-de-Pointes (TdP/VT) for each drug individually in suspected cases (n=480 [223 LQT; 257 TdP/VT], IC025=1.67 for azithromycin and n=136 [53 LQT; 83 TdP/VT], IC025=1.04 for hydroxychloroquine; Figure). Hydroxychloroquine was also associated with conduction disorders (atrioventricular and bundle-branch blocks; n=75, IC025=1.04) and heart failure (n=203, IC025=0.06). No other CV-ADR (including cardiac ischemia and myocarditis)2 was significantly associated with these drugs. The IC values over time and intersecting cases for significant CV-ADRs associated with hydroxychloroquine or azithromycin are presented in the Figure.Download figureDownload PowerPointFigure. Temporal evolution (last accessed March 1, 2020) of the information component (IC) for cardiovascular (CV) adverse drug reactions (ADR) significantly associated with hydroxychloroquine or azithromycin (see statistics below). Whiskers are IC025, IC975. IC025 and IC975 are the lower and upper end of the IC 95% credibility interval, respectively. Significance is IC025>0 (black line). LQT, long QT syndrome; TdP/VT, ventricular tachyarrhythmias (VT) including Torsades-de-Pointes (TdP). Years of first ADR report within VigiBase for hydroxychloroquine and azithromycin were respectively 1967 and 1989 (A). Intersection for selected CV-ADR (IC025>0) in case reports from VigiBase, for hydroxychloroquine (B) and azithromycin (C). Time to onset (in days) between first treatment intake and the CV-ADR associated with hydroxychloroquine or azithromycin (D). *Of the conduction disorders (n=75), 50/75 (67%) were atrioventricular blocks, 24/75 (32%) were bundle-branch blocks, and 1/75 (1%) was a sinus block. Time to onset data are available for hydroxychloroquine and LQT and/or TdP/VT (n=90), for hydroxychloroquine and conduction disorders (n=77), for hydroxychloroquine and heart failure (n=94), and for azithromycin and LQT and/or TdP/VT (n=70). Statistics:2 IC = log2[(Nobserved + 0.5)/(Nexpected + 0.5)], where Nexpected = (Ndrug × Nreaction)/Ntotal, with Nexpected being the number of individual case safety reports (ICSRs) expected for the drug-ADR combination; Nobserved being the actual number of ICSRs observed for the drug-ADR combination; Ndrug being the number of ICSRs for the drug, regardless of ADR; Nreaction being the number of ICSRs for the ADR, regardless of the drug; and Ntotal being the total number of ICSRs in the database.Azithromycin monotherapy was associated with a greater reporting of LQT and/or TdP/VT than hydroxychloroquine monotherapy (736/89 085 [0.8%] versus 263/76 215 [0.3%], respectively; reporting odds ratio, 2.36 [95% CI, 2.05–2.71). The combination of azithromycin and hydroxychloroquine was associated with a greater reporting of LQT and/or TdP/VT reporting than either drug in monotherapy (999/165 300 [0.6%] versus 9/607 [1.5%], reporting odds ratio, 2.48 [95% CI, 1.28–4.79]).Most CV-ADRs reports were in women (516/772, 66.8%). Reporting regions were mostly Americas (549/851, 64.5%) and Europe (185/851, 21.7%). Reporters were mostly healthcare professionals (674/706, 91.1%). In most cases, ADR was attributed to a single drug (492/844, 58.3%). Concurrent reporting of drugs with a known risk of TdP in TdP/VT cases was 31.5% (81/257) with azithromycin and 16.9% (14/83) with hydroxychloroquine.4TTO of LQT and/or TdP/VT with azithromycin was shorter compared with hydroxychloroquine (3 [interquartile range=1;7] versus 51 [IQR=11;113] days, P<0.01). With hydroxychloroquine, TTO of LQT and/or TdP/VT was shorter than heart failure (51 [IQR=11;113] versus 348 [IQR=91;2016] days, P=0.027). This longer TTO observed in hydroxychloroquine may reflect chronic use in lupus or rheumatoid arthritis.The proportion that resulted in death for TdP/VT cases was 8.4% (7/83) with hydroxychloroquine and 20.2% (52/257) with azithromycin versus 0% (0/53) and 5.4% (12/223) for LQT without TdP/VT with hydroxychloroquine and azithromycin, respectively (P<0.001 for both). The corresponding death rate was 20.7% (42/203) for heart failure associated with hydroxychloroquine. The dose of hydroxychloroquine was higher in heart failure compared with LQT and/or TdP/VT cases (200 [IQR=200;400] versus 200 [IQR=200;200] mg/d, P=0.033).The main limitation is that without data on numbers exposed in VigiBase, this work cannot assess the incidence or risk for QT prolongation with these drugs. However, our results are consistent with the facts that these CV-ADRs are found in the US Food and Drug Administration’s labels of hydroxychloroquine and azithromycin, and that both drugs are referenced as having a known risk of TdP on the CredibleMeds website.4 These CV-ADRs are important to bear in mind in the setting of COVID-19 with patients presenting additional risk factors of LQT/TdP caused by inflammation with elevated interleukin-6, hypokalemia, numerous interacting drugs, bradycardia, and higher hydroxychloroquine dosages.5In conclusion, reports of potentially lethal acute cardiac proarrhythmogenic effects leading to ventricular arrhythmias have been described mainly with azithromycin but also with hydroxychloroquine. Their combination yielded an even stronger signal. Hydroxychloroquine was also associated with potentially lethal heart failure when exposure was prolonged over several months.AcknowledgmentsThe authors thank Banook group/Cardiabase, Nancy–France http://www.banookgroup.com/ (Yasmin Khan) for providing the Holter and ECG systems to evaluate prospectively the impact of hydroxychloroquine and azithromycin on ventricular arrhythmia in a current cohort of treated patients with COVID-19, as a follow-up study of this work. They also thank the staff of the AP.HP.Sorbonne clinical investigation center (Maria Martin, Francois Gueguin, Dr Paul Gougis, Dr Bruno Pinna) for their involvement in the latter study and their current effort to better study adverse drug reactions associated with COVID-19 drugs.DisclosuresThe supplied data from VigiBase come from various sources. The likelihood of a causal relationship is not the same in all reports. The information does not represent the opinion of the World Health Organization. The authors report no conflicts.FootnotesData sharing: The data, analytic methods, and study materials are available to other researchers for purposes of reproducing the results or replicating the procedure at http://www.vigiaccess.org/.https://www.ahajournals.org/journal/circJoe-Elie Salem, MD, PhD, Department of Pharmacology, Sorbonne Université, INSERM CIC-1901, AP-HP, Clinical Investigation Center, Pitié-Salpêtrière Hospital, Paris, France, 83 Bld de l’hôpital, 75651 Paris Cedex 13. Email joe-elie.[email protected]frReferences1. Jakhar D, Kaur I. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.Nat Med. 2020; 26:632. doi: 10.1038/s41591-020-0853-0CrossrefMedlineGoogle Scholar2. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.Lancet Oncol. 2018; 19:1579–1589. doi: 10.1016/S1470-2045(18)30608-9CrossrefMedlineGoogle Scholar3. Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, Hidden-Lucet F, Hulot JS, Knollmann BC, Lebrun-Vignes B, et al.. Androgenic effects on ventricular repolarization: a translational study from the International Pharmacovigilance Database to iPSC-Cardiomyocytes.Circulation. 2019; 140:1070–1080. doi: 10.1161/CIRCULATIONAHA.119.040162LinkGoogle Scholar4. Woosley RL, Heise CW, Gallo T, Tate J, Woosley D, Romero KA. QTdrugs List.www.CredibleMeds.org. Accessed June 29, 2020.Google Scholar5. Funck-Brentano C, Salem JE, Nguyen LS, Drici MD, Roden DM. Response to the editorial “COVID-19 in patients with cardiovascular diseases”: Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: a potential risk of Torsades de Pointes.Arch Cardiovasc Dis. 2020; 113:367–368. doi: 10.1016/j.acvd.2020.04.001CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Ferreira‐da‐Silva R, Ribeiro‐Vaz I, Morato M and Junqueira Polónia J (2022) A comprehensive review of adverse events to drugs used in COVID‐19 patients: Recent clinical evidence, European Journal of Clinical Investigation, 10.1111/eci.13763, 52:7, Online publication date: 1-Jul-2022. Matrouf M, Loudiki A, Azriouil M, Laghrib F, Farahi A, Bakasse M, Saqrane S, Lahrich S and El Mhammedi M (2022) Review—Recent Advancements in Electrochemical Sensors for 4-Aminoquinoline Drugs Determination in Biological and Environmental Samples, Journal of The Electrochemical Society, 10.1149/1945-7111/ac71d9, 169:6, (067503), Online publication date: 1-Jun-2022. Baracaldo-Santamaría D, Pabón-Londoño S and Rojas-Rodriguez L (2022) Drug safety of frequently used drugs and substances for self-medication in COVID-19, Therapeutic Advances in Drug Safety, 10.1177/20420986221094141, 13, (204209862210941), Online publication date: 1-Jan-2022. Kamel A, Monem M, Sharaf N, Magdy N and Farid S (2021) Efficacy and safety of azithromycin in Covid‐19 patients: A systematic review and meta‐analysis of randomized clinical trials, Reviews in Medical Virology, 10.1002/rmv.2258, 32:1, Online publication date: 1-Jan-2022. Sowinski K, Kovacs R and Tisdale J (2022) Traditional risk factors for QT interval prolongation and torsades de pointes Torsades de Pointes, 10.1016/B978-0-12-821446-6.00014-6, (79-111), . D’Andrea E, Desai R, He M, Glynn R, Lee H, Weinblatt M and Kim S (2022) Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis, Journal of the American College of Cardiology, 10.1016/j.jacc.2022.04.039, 80:1, (36-46), Online publication date: 1-Jul-2022. Lory P, Lombardi J, Lacroix C, Sanchez-Pena P, Romani S and Grandvuillemin A (2022) Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic, Therapies, 10.1016/j.therap.2021.12.015, 77:3, (301-307), Online publication date: 1-May-2022. Zhao Y, Zhang J, Zheng K, Thai S, Simpson R, Kinlaw A, Xu Y, Wei J, Cui X, Buse J, Stürmer T and Wang T (2022) Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS), Drugs - Real World Outcomes, 10.1007/s40801-022-00300-y, 9:2, (231-241), Online publication date: 1-Jun-2022. Nguyen L, Cooper L, Kerneis M, Funck-Brentano C, Silvain J, Brechot N, Hekimian G, Ammirati E, Ben M’Barek B, Redheuil A, Gandjbakhch E, Bihan K, Lebrun-Vignes B, Ederhy S, Dolladille C, Moslehi J and Salem J (2022) Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database, Nature Communications, 10.1038/s41467-021-27631-8, 13:1, Online publication date: 1-Dec-2022. Baigent C, Windecker S, Andreini D, Arbelo E, Barbato E, Bartorelli A, Baumbach A, Behr E, Berti S, Bueno H, Capodanno D, Cappato R, Chieffo A, Collet J, Cuisset T, de Simone G, Delgado V, Dendale P, Dudek D, Edvardsen T, Elvan A, González-Juanatey J, Gori M, Grobbee D, Guzik T, Halvorsen S, Haude M, Heidbuchel H, Hindricks G, Ibanez B, Karam N, Katus H, Klok F, Konstantinides S, Landmesser U, Leclercq C, Leonardi S, Lettino M, Marenzi G, Mauri J, Metra M, Morici N, Mueller C, Petronio A, Polovina M, Potpara T, Praz F, Prendergast B, Prescott E, Price S, Pruszczyk P, Rodríguez-Leor O, Roffi M, Romaguera R, Rosenkranz S, Sarkozy A, Scherrenberg M, Seferovic P, Senni M, Spera F, Stefanini G, Thiele H, Tomasoni D, Torracca L, Touyz R, Wilde A and Williams B (2021) ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up, Cardiovascular Research, 10.1093/cvr/cvab343, 118:7, (1618-1666), Online publication date: 22-Jun-2022. Ahmadizar F, Soroush N, Ikram M, Kors J, Kavousi M and Stricker B (2020) QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine, European Journal of Preventive Cardiology, 10.1093/eurjpc/zwaa118, 28:17, (1875-1882), Online publication date: 3-Feb-2022. Baigent C, Windecker S, Andreini D, Arbelo E, Barbato E, Bartorelli A, Baumbach A, Behr E, Berti S, Bueno H, Capodanno D, Cappato R, Chieffo A, Collet J, Cuisset T, de Simone G, Delgado V, Dendale P, Dudek D, Edvardsen T, Elvan A, González-Juanatey J, Gori M, Grobbee D, Guzik T, Halvorsen S, Haude M, Heidbuchel H, Hindricks G, Ibanez B, Karam N, Katus H, Klok F, Konstantinides S, Landmesser U, Leclercq C, Leonardi S, Lettino M, Marenzi G, Mauri J, Metra M, Morici N, Mueller C, Petronio A, Polovina M, Potpara T, Praz F, Prendergast B, Prescott E, Price S, Pruszczyk P, Rodríguez-Leor O, Roffi M, Romaguera R, Rosenkranz S, Sarkozy A, Scherrenberg M, Seferovic P, Senni M, Spera F, Stefanini G, Thiele H, Tomasoni D, Torracca L, Touyz R, Wilde A and Williams B (2021) ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up, European Heart Journal, 10.1093/eurheartj/ehab697, 43:11, (1059-1103), Online publication date: 14-Mar-2022. Mucke J and Schneider M (2022) Innovationen in der Arzneimitteltherapie des systemischen Lupus erythematodesInnovations in the pharmaceutical treatment of systemic lupus erythematosus, Der Internist, 10.1007/s00108-021-01250-3, 63:5, (566-572), Online publication date: 1-May-2022. Romani S, Gérard A, Fresse A, Viard D, Van‐Obberghen É, Micallef J, Rocher F and Drici M (2020) Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID‐19 Epidemic, Clinical and Translational Science, 10.1111/cts.12883, 14:1, (163-169), Online publication date: 1-Jan-2021. Rodríguez-Gutiérrez R, Raygoza-Cortez K, Garcia-Leal M, Sáenz-Flores M, Solis R, Flores-Rodríguez A, Álvarez-Villalobos N and González-González J Ivermectin in the Prophylaxis and Treatment of Patients with SARS-CoV-2: A Living Systematic Review and Meta-Analysis, SSRN Electronic Journal, 10.2139/ssrn.3802499 Gutierrez M, Mur I, Mateo M, Vidal F and Domingo P (2021) Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH), Expert Opinion on Pharmacotherapy, 10.1080/14656566.2021.1887140, 22:9, (1127-1141), Online publication date: 13-Jun-2021. Favalli E, Maioli G, Biggioggero M and Caporali R (2021) Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic, Expert Review of Clinical Immunology, 10.1080/1744666X.2021.1908887, 17:6, (561-571), Online publication date: 3-Jun-2021. Janda A, Schuetz C, Canna S, Gorelik M, Heeg M, Minden K, Hinze C, Schulz A, Debatin K, Hedrich C and Speth F (2021) Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists, Rheumatology International, 10.1007/s00296-021-04824-4, 41:5, (911-920), Online publication date: 1-May-2021. Muller R (2021) Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities, Rheumatology International, 10.1007/s00296-021-04868-6, 41:7, (1189-1202), Online publication date: 1-Jul-2021. Prifti E, Fall A, Davogustto G, Pulini A, Denjoy I, Funck-Brentano C, Khan Y, Durand-Salmon A, Badilini F, Wells Q, Leenhardt A, Zucker J, Roden D, Extramiana F and Salem J (2021) Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome, European Heart Journal, 10.1093/eurheartj/ehab588, 42:38, (3948-3961), Online publication date: 7-Oct-2021. Lucien M, Canarie M, Kilgore P, Jean-Denis G, Fénélon N, Pierre M, Cerpa M, Joseph G, Maki G, Zervos M, Dely P, Boncy J, Sati H, Rio A and Ramon-Pardo P (2021) Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings, International Journal of Infectious Diseases, 10.1016/j.ijid.2020.12.087, 104, (250-254), Online publication date: 1-Mar-2021. Yee S, Vora B, Oskotsky T, Zou L, Jakobsen S, Enogieru O, Koleske M, Kosti I, Rödin M, Sirota M and Giacomini K (2021) Drugs in COVID‐19 Clinical Trials: Predicting Transporter‐Mediated Drug‐Drug Interactions Using In Vitro Assays and Real‐World Data, Clinical Pharmacology & Therapeutics, 10.1002/cpt.2236, 110:1, (108-122), Online publication date: 1-Jul-2021. Zahr N, Urien S, Llopis B, Pourcher V, Paccoud O, Bleibtreu A, Mayaux J, Gandjbakhch E, Hekimian G, Combes A, Benveniste O, Saadoun D, Allenbach Y, Pinna B, Cacoub P, Funck-Brentano C and Salem J (2021) Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19, Therapies, 10.1016/j.therap.2021.01.056, 76:4, (285-295), Online publication date: 1-Jul-2021. Asili P, Mirahmad M, Tabatabaei-Malazy O, Manayi A, Haghighat E, Mahdavi M and Larijani B (2021) Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review, DARU Journal of Pharmaceutical Sciences, 10.1007/s40199-021-00422-8, 29:2, (449-467), Online publication date: 1-Dec-2021. Fiolet T, Guihur A, Rebeaud M, Mulot M, Peiffer-Smadja N and Mahamat-Saleh Y (2021) Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis, Clinical Microbiology and Infection, 10.1016/j.cmi.2020.08.022, 27:1, (19-27), Online publication date: 1-Jan-2021. Naveen R, Verma A, Raza H, Chengappa K, R Naidu G, Sharma S, Goel A, Misra D, Sharma A, Gupta L and Agarwal V (2021) Prescription practices, experiences, and perspectives on the usage of hydroxychloroquine among rheumatologists and other specialists, Indian Journal of Rheumatology, 10.4103/injr.injr_319_20, 16:2, (169), . Besançon L, Peiffer-Smadja N, Segalas C, Jiang H, Masuzzo P, Smout C, Billy E, Deforet M and Leyrat C (2021) Open science saves lives: lessons from the COVID-19 pandemic, BMC Medical Research Methodology, 10.1186/s12874-021-01304-y, 21:1, Online publication date: 1-Dec-2021. Liu Y, Zhang R, Hancox J and Zhang H (2021) In silico investigation of pro-arrhythmic effects of azithromycin on the human ventricle, Biochemistry and Biophysics Reports, 10.1016/j.bbrep.2021.101043, 27, (101043), Online publication date: 1-Sep-2021. Syraeva G, Mishinova S, Kolbin A and Eremenko E (2021) Safety profile assessment of drug products used for the pathogenetic treatment of COVID19, Clinical Microbiology and Antimicrobial Chemotherapy, 10.36488/cmac.2021.3.314-329, 23:3, (314-329), . Sallard E, Belhadi D, Lescure F, Yazdanpanah Y and Peiffer-Smadja N (2021) Clinical trial protocols of repurposed prophylaxis for COVID-19: A review, Infectious Diseases Now, 10.1016/j.medmal.2020.09.013, 51:1, (7-13), Online publication date: 1-Feb-2021. Desmarais J, Rosenbaum J, Costenbader K, Ginzler E, Fett N, Goodman S, O’Dell J, Pineau C, Schmajuk G, Werth V, Link M and Kovacs R (2021) American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity, Arthritis & Rheumatology, 10.1002/art.41934, 73:12, (2151-2160), Online publication date: 1-Dec-2021. El-Goly A (2021) Lines of Treatment of COVID-19 Infection Covid-19 Infections and Pregnancy, 10.1016/B978-0-323-90595-4.00002-9, (91-144), . Viskin S (2020) Important Developments in Long QT Syndrome, Circulation, 142:25, (2416-2419), Online publication date: 22-Dec-2020. Ye Q, Lu D, Shang S, Fu J, Gong F, Shu Q and Mao J (2020) Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment, ESC Heart Failure, 10.1002/ehf2.12960, 7:6, (3464-3472), Online publication date: 1-Dec-2020. Drici M (2020) Estimates of population‐based incidence of malignant arrhythmias associated with medication use – a narrative review, Fundamental & Clinical Pharmacology, 10.1111/fcp.12582, 34:4, (416-417), Online publication date: 1-Aug-2020. Machiels J, Bleeker-Rovers C, ter Heine R, Rahamat-Langendoen J, de Mast Q, ten Oever J, Bousema T, van Crevel R and Wertheim H (2020) Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?, International Journal of Antimicrobial Agents, 10.1016/j.ijantimicag.2020.106056, 56:1, (106056), Online publication date: 1-Jul-2020. Furtado R, Berwanger O, Fonseca H, Corrêa T, Ferraz L, Lapa M, Zampieri F, Veiga V, Azevedo L, Rosa R, Lopes R, Avezum A, Manoel A, Piza F, Martins P, Lisboa T, Pereira A, Olivato G, Dantas V, Milan E, Gebara O, Amazonas R, Oliveira M, Soares R, Moia D, Piano L, Castilho K, Momesso R, Schettino G, Rizzo L, Neto A, Machado F and Cavalcanti A (2020) Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial, The Lancet, 10.1016/S0140-6736(20)31862-6, 396:10256, (959-967), Online publication date: 1-Oct-2020. Zayed M and Iohara K (2020) Immunomodulation and Regeneration Properties of Dental Pulp Stem Cells: A Potential Therapy to Treat Coronavirus Disease 2019, Cell Transplantation, 10.1177/0963689720952089, 29, (096368972095208), Online publication date: 1-Jan-2020. (2020) Hydroxychloroquine- and azithromycin-related heart disorders, Reactions Weekly, 10.1007/s40278-020-79294-y, 1807:1, (8-8), Online publication date: 1-Jun-2020. Offerhaus J, Wilde A and Remme C (2020) Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk, Heart Rhythm, 10.1016/j.hrthm.2020.07.001, 17:9, (1480-1486), Online publication date: 1-Sep-2020. Sharma A, Kumar Sharma S, Shi Y, Bucci E, Carafoli E, Melino G, Bhattacherjee A and Das G (2020) BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?, Cell Death & Disease, 10.1038/s41419-020-2720-9, 11:7, Online publication date: 1-Jul-2020. Funck-Brentano C, Nguyen L and Salem J (2020) Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19, The Lancet, 10.1016/S0140-6736(20)31528-2, 396:10245, (e2-e3), Online publication date: 1-Jul-2020. El Tabaa M and El Tabaa M (2020) New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19, European Journal of Pharmacology, 10.1016/j.ejphar.2020.173615, 889, (173615), Online publication date: 1-Dec-2020. Park J (2020) Current Treatments of Coronavirus Disease 2019 in Elderly, Korean Journal of Clinical Geriatrics, 10.15656/kjcg.2020.21.2.54, 21:2, (54-64), Online publication date: 30-Dec-2021. Waters L and Rockstroh J (2020) COVID‐19 research: an opinion piece, HIV Medicine, 10.1111/hiv.12913, 21:8, (536-540), Online publication date: 1-Sep-2020. Lecronier M, Beurton A, Burrel S, Haudebourg L, Deleris R, Le Marec J, Virolle S, Nemlaghi S, Bureau C, Mora P, De Sarcus M, Clovet O, Duceau B, Grisot P, Pari M, Arzoine J, Clarac U, Boutolleau D, Raux M, Delemazure J, Faure M, Decavele M, Morawiec E, Mayaux J, Demoule A and Dres M (2020) Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis, Critical Care, 10.1186/s13054-020-03117-9, 24:1, Online publication date: 1-Dec-2020. GALLUS S, CLAVENNA A and LUGO A (2020) Does hydroxychloroquine reduce mortality for COVID-19?, European Journal of Internal Medicine, 10.1016/j.ejim.2020.10.015, 82, (21-22), Online publication date: 1-Dec-2020. Binois Y, Hachad H, Salem J, Charpentier J, Lebrun-Vignes B, Pène F, Cariou A, Chiche J, Mira J and Nguyen L (2020) Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19, Kidney International Reports, 10.1016/j.ekir.2020.07.035, 5:10, (1787-1790), Online publication date: 1-Oct-2020. Li X, Wang Y, Agostinis P, Rabson A, Melino G, Carafoli E, Shi Y and Sun E (2020) Is hydroxychloroquine beneficial for COVID-19 patients?, Cell Death & Disease, 10.1038/s41419-020-2721-8, 11:7, Online publication date: 1-Jul-2020. Campione E, Lanna C, Cosio T, Rosa L, Conte M, Iacovelli F, Romeo A, Falconi M, Del Vecchio C, Franchin E, Lia M, Minieri M, Chiaramonte C, Ciotti M, Nuccetelli M, Terrinoni A, Iannuzzi I, Coppeta L, Magrini A, Bernardini S, Sabatini S, Rosapepe F, Bartoletti P, Moricca N, Di Lorenzo A, Andreoni M, Sarmati L, Miani A, Piscitelli P, Squillaci E, Valenti P and Bianchi L (2021) Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence, International Journal of Environmental Research and Public Health, 10.3390/ijerph182010985, 18:20, (10985) Canedo-Marroquín G, Saavedra F, Andrade C, Berrios R, Rodríguez-Guilarte L, Opazo M, Riedel C and Kalergis A (2020) SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments, Frontiers in Immunology, 10.3389/fimmu.2020.569760, 11 Singh B, Ryan H, Kredo T, Chaplin M and Fletcher T (2021) Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD013587.pub2, 2021:2 Belenkov Y, Menshikova I, Ilgisonis I, Naimann Y, Pak Y, Kolosova I and Rakovskaya A (2020) The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19, Sechenov Medical Journal, 10.47093/2218-7332.2020.11.2.29-39, 11:2, (29-39) Khadka S, Shrestha D, Budhathoki P and Rawal E (2020) Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety, Clinical Pharmacology: Advances and Applications, 10.2147/CPAA.S269156, Volume 12, (115-121) Salahshoori I, Mobaraki-Asl N, Seyfaee A, Mirzaei Nasirabad N, Dehghan Z, Faraji M, Ganjkhani M, Babapoor A, Shadmehr S and Hamrang A (2021) Overview of COVID-19 Disease: Virology, Epidemiology, Prevention Diagnosis, Treatment, and Vaccines, Biologics, 10.3390/biologics1010002, 1:1, (2-40) Paumgartten F (2022) The ethical limits of physicians’ autonomy and the Brazilian Federal Council of Medicine, Cadernos de Saúde Pública, 10.1590/0102-311xen259021, 38:5 Nguyen L, Raia L, Lebrun-Vignes B and Salem J (2021) Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review, Frontiers in Pharmacology, 10.3389/fphar.2020.619649, 11 Severa M, Farina C, Salvetti M and Coccia E (2020) Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?, Frontiers in Immunology, 10.3389/fimmu.2020.01459, 11 Jozwiak M, Geri G, Laghlam D, Boussion K, Dolladille C and Nguyen L (2022) Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review, Frontiers in Medicine, 10.3389/fmed.2022.826446, 9 Italia L, Tomasoni D, Bisegna S, Pancaldi E, Stretti L, Adamo M and Metra M (2021) COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.713560, 8 Moll-Bernardes R, de Sousa A, Macedo A, Lopes R, Vera N, Maia L, Feldman A, Arruda G, Castro M, Pimentel-Coelho P, de Albuquerque D, de Paula T, Furquim T, Loures V, Giusti K, de Oliveira N, De Luca F, Kotsugai M, Domiciano R, Santos M, de Souza O, Bozza F, Luiz R and Medei E (2021) IL-10 and IL-12 (P70) Levels Predict the Risk of Covid-19 Progression in Hypertensive Patients: Insights From the BRACE-CORONA Trial, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.702507, 8 July 21, 2020Vol 142, Issue 3Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.120.048238PMID: 32442023 Originally publishedMay 22, 2020 KeywordshydroxychloroquineazithromycinphamacovigilancecardiotoxicityPDF download Advertisement SubjectsArrhythmiasElectrophysiologyEpidemiologyVentricular Fibrillation
Referência(s)